Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults

NCT06020118 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT06020118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06020118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults
Lead sponsor
Duke University
Phase
Phase 4
Overall status
Completed
Start date
September 25, 2023
Completion date
May 17, 2024
Enrollment
455 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, influenza